Last reviewed · How we verify
Placebo for Tamsulosin
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in Phase 3 trial for benign prostatic hyperplasia (comparison to Tamsulosin).
At a glance
| Generic name | Placebo for Tamsulosin |
|---|---|
| Sponsor | IlDong Pharmaceutical Co Ltd |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. It relies on the placebo effect—the psychological and physiological response to the expectation of treatment—rather than any direct molecular mechanism. In this Phase 3 trial, placebo serves as the comparator arm against Tamsulosin, an alpha-1A adrenergic receptor antagonist used for benign prostatic hyperplasia.
Approved indications
- Control arm in Phase 3 trial for benign prostatic hyperplasia (comparison to Tamsulosin)
Common side effects
Key clinical trials
- Study to Prevent Postoperative Urinary Retention (PHASE4)
- Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment (PHASE4)
- Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery (PHASE4)
- Deprescribing Tamsulosin in Older Men (PHASE4)
- Preoperative Tamsulosin to Prevent Postoperative Urinary Retention After Surgery For Pelvic Floor Disorders (EARLY_PHASE1)
- Peri-operative Tamsulosin and Impact on Voiding Trial After Same-day Urogynecology Surgery (PHASE3)
- Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms (PHASE3)
- A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Tamsulosin CI brief — competitive landscape report
- Placebo for Tamsulosin updates RSS · CI watch RSS
- IlDong Pharmaceutical Co Ltd portfolio CI